Camena Bioscience

Camena Bioscience develops a nucleic acid synthesis technology platform called gSynth that delivers high-fidelity, transfection-ready DNA three times faster than traditional methods. The platform addresses bottlenecks in the design-build-test-learn (DBTL) cycle by enabling sequence-perfect DNA synthesis regardless of structural complexity, supporting applications in personalized mRNA vaccines, cell and gene therapies, and CRISPR screening. gSynth can synthesize long, complex, and highly repetitive sequences including GC-rich promoters, enhancers, terminators, and Cas12a constructs that are difficult to manufacture with traditional chemical synthesis. The company serves drug discovery labs and has recently appointed Gregory P. McGuinness as CEO to lead commercialization of the gSynth platform for AI-driven antibody discovery. Founded in 2016 and headquartered in Cambridge, United Kingdom, Camena Bioscience has raised approximately $10 million in Series A funding from investor Mercia.